TOP HEADLINES

Featured Story

Tekmira hammers out a way to get its Ebola drug to patients

Tekmira, developer of an RNAi treatment for Ebola, has come to terms with regulators on an access program for its in-development drug, allowing the company to provide doses to patients who have contracted the deadly virus.

Amgen pushes for early FDA OK of leukemia drug blinatumomab

Bolstered by a breakthrough drug designation at the FDA, Amgen is following through with a new drug application for its leukemia drug blinatumomab, hoping that promising Phase II data will be enough to push this program past the goal line on a greatly accelerated development schedule.

Regeneron touts its allergy drug as a blockbuster in waiting

While Eylea brings in the money and the cardio contender alirocumab grabs the headlines, Regeneron believes one of its less heralded pipeline treatments could eventually outgrow both, treating the underlying cause behind a handful of chronic diseases.

Auxilium shakes off Endo's $2.2B offer and affirms its eye on QLT

Auxilium Pharmaceuticals has no intention of accepting a multibillion-dollar bid from Endo, the company said, preferring to stay the course and pull off an en-vogue tax inversion as it looks to cut costs.

Merck KGaA bags Sigma-Aldrich's global lab services, manufacturing ops in $17B buyout

Merck KGaA has come up with its long-awaited buyout deal, acquiring the life sciences services outfit Sigma-Aldrich for $17 billion.

MORE NEWS

From Our Sister Sites

FiercePharma

Amgen is hoping to redeem its drug development rep by going to the FDA with an application for its new leukemia drug blinatumomab based on promising Phase II data, FierceBiotech reports.

FiercePharma

Generic drugmaker Par Pharmaceutical is throwing in the towel in its long-running fight with Santarus ($SNTS) over its heartburn med Zegerid, and $100 million along with it. It reported today that the payment will settle their back-and-forth patent suit.